Analyst Price Target is C$20.00
▲ +86.92% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BELLUS Health in the last 3 months. The average price target is C$20.00, with a high forecast of C$24.00 and a low forecast of C$16.00. The average price target represents a 86.92% upside from the last price of C$10.70.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in BELLUS Health. This Buy consensus rating has held steady for over two years.
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.